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a-1-antitrypsin deﬁciency (AATD) (PiZZ) emphysema patient was treated with 60–120mg/
kg body weight of Prolastins weekly or every second week over 8 years (from 1992 until
2000). The therapy was re-started in summer 2002 and terminated in autumn 2004. Results
from lung function tests, liver enzymes and plasma inﬂammatory markers are presented
from years 2002 and 2004, and 7 months after termination of treatment. No changes in
lung function tests, liver enzymes or plasma inﬂammatory markers were observed during a
period of study. Blood neutrophils were isolated in October 2004, before and after
Prolastins infusion, and in October 2005. Neutrophils were analyzed for baseline and
zymosan-induced interleukine-8 (IL-8) release. In response to zymosan neutrophils isolated
after Prolastins infusion released signiﬁcantly lower levels of IL-8 than neutrophils
obtained before Prolastins infusion or after termination of treatment. Thus, blood
neutrophils exhibit diminished capacity to release IL-8 after direct use of the
augmentation therapy.
& 2008 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
a, tumor necrosis factor-alpha; MCP-1, monocyte chemoattractant protein-1; AATD, a-1-antitrypsin
forced expiratory volume in 1 s; TLCO-SB, the diffusion capacity for carbon monoxide assessed by single
l lung capacity; HRCT, high-resolution computed tomography; LPS, lipopolysaccharide; AST, aspartate
ansferase; GGT, gamma glutamyl-transpeptidase; SLPI, secretory leukocyte protease inhibitor; ACT, a-
eroxidase; LTB4, leukotriene B4.
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Figure 1 A schematic presentation of study design.
Table 1 Results of lung function tests during treatment
and after treatment termination.
Parameters measured Years
1992 2002 2004 2005
FEV1 (L) 2.2 1.5 1.6 1.6
(% predicted) (59) (52) (55) (55)
VC (L) 5.2 4.8 5.1 5.0
(% predicted) (106) (104) (111) (109)
FEV1/VC(%) 42 27 31 31
TLC (L) 8.4 8.6 8.4 7.9
(% predicted) (113) (120) (118) (111)
RV (L) 3.2 3.8 3.4 2.5
(% predicted) (129) (143) (128) (94)
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a-1-Antitrypsin deﬁciency (AATD) is a relatively common
genetic disorder which predisposes individuals to the
development of lung emphysema and liver diseases.1,2 The
most severe a-1-antitrypsin (AAT) deﬁciency variant, the Z
mutation (Glu342-Lys), is characterized by 80–90% lower
levels of circulating AAT that is ﬁve-fold less effective at
inhibiting neutrophil elastase than AAT of the normal M
genotype.3,4 Therefore, it is proposed that in AATD, the
protease–antiprotease balance is disturbed which leads to
excessive proteolytic activity and alveolar damage. Based
on the protease–antiprotease theory replacement therapy
with puriﬁed human plasma AAT was introduced during the
1980s.5 It is conﬁrmed that replacement therapy in AATD
individuals with emphysema increases serum and epithelial
lining ﬂuid AAT levels, which are necessary to protect lungs
from neutrophil elastase damage.6 Clinical reports from
non-randomized studies show that use of AAT replacement
slower decline in lung function in individuals with an forced
expiratory volume in 1 s (FEV1) of 35–49% predicted, and
reduces incidence of lung infections and mortality.7–9 We
have previously demonstrated that Prolastins signiﬁcantly
inhibits nasal IL-8 release in response to pure lipopolysac-
charide (LPS) challenge.10 A recent study by Griese et al.11
looking at the response of patients with cystic ﬁbrosis to
inhaled AAT suggests improvement in several markers of
disease activity including airway inﬂammation and reduced
pseudomonas.
Here we describe a non-smoking male, 61 years of age,
with ZZ AATD-related emphysema who received AAT
augmentation therapy from 1992 until 2000, and from
2002 until autumn 2004.TLCO-SB 8.6 6.6 5.5 5.8
(mmol/min/kPa) (% predicted) (93) (76) (63) (67)
FEV1 ¼ forced expiratory volume in 1 s; VC ¼ vital capacity;
TLC ¼ total lung capacity; RV ¼ residual volume; TLCO-
SB ¼ diffusion capacity for carbon monoxide assessed by
single breath.Case report
A non-smoking 61-year-old male patient with severe AATD
(PiZZ) emphysema was recruited for replacement therapy in
1992 after signing a full informed consent. The patient
received infusions until 2000 when the availability of human
AAT, Prolastins (Bayer Pharmaceuticals, West Haven, CT,
USA) was reduced. The therapy was re-started in summer
2002 and terminated in autumn 2004 by request from the
patient because of well-being and to avoid time consuming
visits at the hospital. The infusions of AAT were well
tolerated, no side-effects observed during a period of
treatment. A schematic presentation of study design is
shown in Figure 1.
Between the years 2002 and 2004 the patient was treated
once or every second week with intravenous infusions of
Prolastins, 60–120mg/kg body weight. Spirometry was
performed in the clinic before treatment was started in
1992, before treatment was re-started in 2002, during
treatment 2002 and 2004, and ﬁnally, 1 year after the
termination of treatment, in 2005. As shown in Table 1, no
signiﬁcant changes occurred in FEV1 during the observed
period of time. However, compared to initial lung function
tests in 1992, FEV1 (% of predicted) and vital capacity (VC)
(% of predicted) changed from 59% to 55% and from 106% to
109%, respectively. The diffusion capacity for carbon
monoxide assessed by single breath (TLCO-SB), the residualvolume (RV) and the total lung capacity (TLC) decreased
between 2002 and 2005 (Table 1). High-resolution
computed tomography (HRCT) was performed before treat-
ment was re-started in 2002, and after termination of
treatment in 2004. Examination data from 2001 showed
diffused, mainly basal emphysema, and only a marginal
progress of the emphysema was notiﬁed during re-examina-
tion in 2004.
The analysis of liver function was undertaken according to
standardized methods at the Department of Clinical
Chemistry, Malmo¨ University Hospital, Sweden. Levels of
aspartate aminotransferase (AST), alanine aminotransferase
(ALT) and gamma glutamyl-transpeptidase (GGT) ranged
from 0.79 to 1.00 mkat/L, 0.79–1.10 and 0.88–1.21 mkat/L,
respectively. After termination of treatment an ultrasound
was performed to investigate possible signs of liver disease.
According to examination data no signs of steatosis or liver
cirrhosis were observed.
In 2004, plasma was collected during 6 weeks before and
after infusions with Prolastins and once a month after
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determine the levels of inﬂammatory markers (tumor
necrosis factor-alpha (TNF-a), interleukin (IL)-1b, IL-6, IL-
8, IL-10, and monocyte chemoattractant protein-1 (MCP-1))
by DuoSet ELISA kits (R&D Systems, MN, USA; detection
levels 15.625, 3.906, 9.375, 31.250, 62.500, and 15.625 pg/
mL). The levels of TNF-a, IL-1b, IL-6, IL-8, IL-10 and MCP-1
were below detection limits. Plasma levels of protease
inhibitors, such as secretory leukocyte protease inhibitor
(SLPI), a-1-antichymotrypsin (ACT) and AAT, were analyzed
by using Quantikine Immunoassay human SLPI (R&D Systems,
MN, USA; detection level 62.500 pg/mL) and rocket im-
munoelectrophoresis as previously described by Laurell.12
Plasma levels of SLPI and ACT remained constant and were
measured as 49.09 (74.71 SD, n ¼ 6 weeks period) ng/mL
and 0.34 (70.04 SD, n ¼ 6 week period)mg/mL, respec-
tively.
The plasma AAT concentration had a baseline value of
0.24mg/mL in 1992. During the augmentation therapy the
average plasma AAT concentration was 0.67 (70.09 SD,
n ¼ 6 weeks)mg/mL before infusion and 1.95 (70.11 SD,
n ¼ 6 weeks)mg/mL after infusion. After treatment termi-
nation, between December 2004 and June 2005, the average
plasma concentration returned to the baseline 0.29 (70.07
SD)mg/mL.
Non-denaturing 7.5% PAGE followed by western blot was
used to characterize the molecular proﬁle of plasma AAT.
Brieﬂy, blots were developed using polyclonal rabbit anti-
human AAT antibody (DakoCytomation, A/S, Denmark) or
monoclonal mouse ATZ11 antibody, available in our labora-
tory,13 followed by incubation with horseradish peroxidasenAAT
nAAT
1 2 3 4 5 6 7 8
Figure 2 Representative examples of molecular forms of plasma
replacement therapy. Plasma samples were analyzed by non-denatu
mouse antibodies against human AAT. (a) and (c) Plasma obtained w
detected by using rabbit polyclonal and mouse monoclonal ATZ11
obtained monthly after termination of replacement therapy. AAT is d
antibodies against human AAT, respectively.(HRP)-conjugated antibodies; polyclonal swine anti-rabbit
or rabbit anti-mouse immunoglobulins (DakoCytomation,
A/S Denmark). Protein bands were visualized using ECL plus
Western blotting detection system (Amersham Biosciences,
Sweden). As illustrated in Figures 2a and c, we found no
remarkable differences in AAT proﬁle before and after AAT
infusion. One can only notice that after infusion the levels of
certain molecular forms of AAT occurred in higher amounts
as compared to those before infusion. Furthermore, no
difference was detected in electrophoresis proﬁles of AAT
after treatment termination (Figures 2b and d).
Blood neutrophils were isolated before and after AAT
infusion and 11 months after termination of treatment, as
previously described14 (Figure 1). Isolated neutrophils
(2.5 106 cells/well) were cultured alone or in the presence
of zymosan 0.1mg/mL for 18 h at 37 1C 5% CO2. Neutrophil
supernatants were analyzed to determine IL-8 levels by
using DuoSet ELISA kits (R&D Systems, MN, USA; detection
levels 62.500 pg/mL). Non-stimulated neutrophils secreted
similar amounts of IL-8 independently whether they were
isolated during augmentation therapy, before and after
Prolastin infusion (1112.4735.4 versus 742.9723.8 pg/ml)
or after termination of treatment (1511.37183.1 pg/ml)
(Figure 3).
In the next set of experiments, neutrophils were
stimulated with zymosan. As compared to base line,
neutrophils isolated before Prolastin infusion, and speciﬁ-
cally after treatment termination, released higher levels of
IL-8 in response to zymosan than neutrophils isolated
directly after Prolastin infusion (po0.05 and 0.01, respec-
tively) (Figure 3).1. Week 1, before infusion
2. Week 1, after infusion
3. Week 2, before infusion
4. Week 2, after infusion    
5. Week 3, before infusion
6. Week 3, after infusion
7. December 2004
8. January 2005
9. February 2005
10. March 2005
11. April 2005
12. May 2005
13. June 2005
9 10 11 12 13
AAT, before and after AAT infusion, and after termination of
ring PAGE 7.5% following western blot by using speciﬁc rabbit or
eeks 1, 2 and 3, before and after augmentation therapy. AAT is
antibodies against human AAT, respectively. (b) and (d) Plasma
etected by using rabbit polyclonal and mouse monoclonal ATZ11
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Figure 3 IL-8 release from blood neutrophil isolated during treatment and after treatment termination. Neutrophils were cultured
alone or in the presence of zymosan 0.1mg/mL for 18 h at 37 1C 5% CO2. Neutrophil supernatants were analyzed to determine IL-8
levels by using DuoSet ELISA kits (R&D Systems, MN, USA; detection levels 62.500 pg/mL).
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We present here the non-smoking emphysema patient with
severe AATD that received intravenous weekly or biweekly
infusions of human AAT, Prolastins, from 1992 until 2000,
and during 2002–2004. Various studies suggest a minimum
plasma threshold of 11 mmol/L, which provides the body
with sufﬁcient circulating AAT to protect the lung.15 The
analysis of plasma AAT levels revealed that during treatment
the concentration of AAT reached the value that generally is
considered to be the protective threshold. Treatment has
been effective in maintaining AAT levels above the
‘‘protective’’ threshold for the entire interval between
infusions. However, the important question, which has not
yet fully been answered, is whether this biochemical
‘‘normalization’’ inﬂuences the pathogenic processes
thought to be of importance in the development and
progression of lung disease. During the augmentation
therapy we did not observe any signiﬁcant changes in
FEV1, VC and FEV1/VC; however, the TLCO-SB decreased and
HRCTconﬁrmed the progression of emphysema. To date, the
clinical efﬁcacy of augmentation therapy is suggested by the
concordant results of several observational studies showing
that recipients experience a slower rate of decline in FEV1,
slower loss of lung density, fewer lung infections, enhanced
survival, and reduced lung inﬂammation as measured by
biomarkers in biological ﬂuids.7,8,16,17
It is important to point out that no exacerbations were
recorded in our patient between the years 2002 and 2005.
Moreover, the levels of plasma inﬂammatory markers, such
as TNF-a, IL-1b, IL-6, IL-8, IL-10, MCP-1, SLPI and ACT, were
very low or below detection limits. Exacerbations occur
frequently in patients with AATD and are associated with
signiﬁcantly worsening health status. Indeed, previous
studies have demonstrated that acute exacerbations are
associated with more inﬂammation in AATD,18 and the loss of
lung function.19 Lieberman8 reported that individuals with
AATD-associated emphysema had a reduced frequency of
lung infections per year from three to ﬁve infections to zero
to one infection after receiving replacement therapy for41
year. Together these ﬁndings support the concept that
augmentation therapy may reduce chronic lung inﬂamma-
tion in AATD emphysema patients, lower frequency of
exacerbations and, therefore, may improve patient’s lifequality. Thus future clinical trials should include exacerba-
tions as an important outcome measure in patients under-
going augmentation therapy.
We show here that circulating blood neutrophils isolated
directly after augmentation therapy release much lower IL-8
levels when activated as compared to neutrophils isolated
before therapy. Neutrophils are the primary cell type that is
recruited to the airways during the acute stages of
respiratory infections20 and this is likely in response to
chemotactic factors, such as IL-8 and leukotriene B4
(LTB4).
21 Therefore, the diminished capacity of neutrophils
to release IL-8 after use of the augmentation therapy may
play a relevant role in the neutrophil recruitment and
activation in AATD emphysema. In summary, we show that
AAT augmentation restores plasma concentrations of AAT,
and that this is associated with a reduction in IL-8 release by
circulating blood neutrophils. Our data, therefore, provide
supporting biochemical evidence concerning the efﬁcacy of
augmentation therapy.Conﬂict of interest statement
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